| Cat.No. | Name | Information |
|---|---|---|
| M3517 | Lapatinib | Lapatinib (GW572016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
| M1802 | Lapatinib Ditosylate | Lapatinib Ditosylate (CAS 388082-78-8) is a selective and effective inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM) and ErbB-4 kinase (Ki = 347 nM). |
| M1749 | Gefitinib | Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. |
| M5621 | Erlotinib (CP-358774) | Erlotinib (CP-358774) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
| M1913 | Neratinib | Neratinib (HKI-272) is an orally available, irreversible inhibitor of Her 2 tyrosine kinase. |
| M1850 | WZ4002 | WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. |
| M1869 | Dacomitinib | Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. |
| M5307 | Afatinib dimaleate | Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. |
| M2424 | AZD9291 (Osimertinib) | Osimertinib (AZD-9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR, respectively. |
| M1677 | Afatinib (BIBW 2992) | Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. |
| M54702 | VRN-11 | VRN-11 is an EGFR C797S inhibitor. |
| M54701 | TRX-221 | TRX-221 is an EGFR C797S inhibitor. |
| M54700 | TAS-3351 | TAS-3351 is an EGFR C797S inhibitor. |
| M54680 | Larotinib mesylate hydrate | Larotinib mesylate hydrate is a potent, broad-spectrum, orally active tyrosine kinase inhibitor (TKI) that primarily targets EGFR with an IC50 of 0.6 nM. |
| M54493 | HER2/neu (654-662) GP2 | HER2/neu (654-662) GP2 is a nine amino acid peptide, induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers. |
| M54265 | EGFR Protein Tyrosine Kinase Substrate | EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. |
| M52829 | Epidermal Growth Factor Receptor Peptide (985-996) | Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR). |
| M52828 | Nelipepimut-S | Nelipepimut-S is a peptide vaccine which targets HER2. |
| M52827 | pp60 (v-SRC) Autophosphorylation Site, Phosphorylated | pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. |
| M52826 | Lys-Arg-Thr-Leu-Arg-Arg | Lys-Arg-Thr-Leu-Arg-Arg (KRTLRR) is a hexapeptide. |
| M52825 | ErbB-2-binding peptide | ErbB-2-binding peptide (HER2-binding peptide) is a tumor-binding peptide. |
| M49648 | BI-1622 | BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. |
| M49472 | LY3164530 | LY3164530 is a bispecific antibody targeting c-MET/EGFR that fuses scFv (cetuximab) to the N-terminal end of the heavy chain of emibetuzumab, resulting in a 2+2 symmetric bis-antibody, which is of the IgG4 subtype, and has little to no associated effects such as ADCC. |
| M49471 | AZD9592 | AZD9592 is a potentially first-in-class EGFR/c-MET bispecific antibody coupling (ADC), along with a novel topoisomerase 1 load, that can be used for a variety of tumor-related studies. |
| M49470 | MCLA-129 | MCLA-129 is a 1+1 asymmetric c-Met/EGFR bispecific antibody that can be used in a variety of tumor-related studies. |
| M49469 | CKD-702 | CKD-702 is a c-Met/EGFR bispecific antibody that can be used in studies related to non-small cell lung cancer and gastric cancer. |
| M45386 | Rezivertinib | Rezivertinib is an orally effective, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) with high potency against common activating EGFR and resistant T790M mutations.Rezivertinib exhibits excellent CNS penetration and antitumor activity. |
| M45311 | EGFR-IN-57 | EGFR-IN-57 is a potent, orally active EGFR-TK inhibitor with an IC50 value of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ, and tubulin polymerization with an IC50 value of 0.087, 0.171, 0.13, and 3.61 µM, respectively. In addition, EGFR-IN-57 induced G2/M and pre-G1 cycle arrest and apoptosis in cancer cells. |
| M45226 | JIN-A02 | JIN-A02 is a novel, orally active, fourth-generation EGFR tyrosine kinase inhibitor that efficiently targets the EGFR C797S mutation in non-small cell lung cancer. |
| M45211 | ABSK112 | ABSK112 is a potentially best-in-class, orally active, selective EGFR Exon20ins inhibitor with better brain entry properties, higher selectivity against wild-type EGFR, and broader Exon20ins mutation coverage profile. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
